Sino Biopharmaceutical Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sino Biopharmaceutical Limited
The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.
Mereo will reduce its headcount by 40% to focus on its lead programs while NeuBase revealed a 60% workforce reduction to extend its cash runway. Also, Invivyd (formerly Adagio), Greenlight and BioMarin announced job cuts, while Otonomy and others planned strategic shifts.
When the sector worries about regulation it is usually about drug development and registration. But governments also regulate on monopolistic positions in life sciences. Adding to that, national security enforcement is now rising.
Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals
- Drug Delivery
- Generic Drugs
Drug Discovery Technologies
- Natural Products
- Molecular Diversity
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Beijing Tide Pharmaceutical Co Ltd, invoX Pharma
- Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd, Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd, Qingdao Chia Tai Haier Pharmaceutical Co Ltd, Jiangsu Chia Tai Qing Jiang Pharmaceutical Co Ltd, etc. Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd